Studies have described a spectrum of thrombotic complications associated with TPO-RA therapy, including pulmonary embolism, deep vein thrombosis, extensive CVST, portal vein thrombosis, ischemic stroke, and myocardial infarction [9,10]. This evidence concerns the gene TPO and Portal vein thrombosis.